Team

Milton Lönnroth is the Co-Founder and CEO of Atley Solutions. He holds a First-Class Honours Bachelor’s degree in Biochemical Engineering from University College London and has studied Knowledge-Based Entrepreneurship at the School of Business, Economics and Law at the University of Gothenburg.

As the company’s first employee, Milton has guided Atley Solutions from its inception to becoming a global leader in At-211 radiopharmaceuticals.

Björn Eriksson serves as the Chief Technology Officer at Atley Solutions. He earned his PhD in Analytical Chemistry from Karlstad University, where his research focused on capillary liquid chromatography and capillary electrophoresis. Following his doctoral studies, Björn worked as an Analytical Chemist at Cambrex, collaborating with process chemists and engineers to upscale API and intermediate processes. He then served as CTO at hemCheck Sweden AB, where he played a crucial role in advancing products from early prototypes to market-ready stages. In 2020, Björn joined Atley Solutions as CTO, where he coordinates hardware and software development, contributing his extensive experience in product development within life science startups.

Julia Fransson serves as the Chief Operating Officer at Atley Solutions. She holds a Master of Science in Entrepreneurship and Business Design and a Bachelor of Science in Biotechnology, both from Chalmers University of Technology.

Julia brings extensive experience in the life sciences sector, with a strong background in operations, strategy, and project management. Prior to joining Atley, she served as Director of Business Development at Cereno Scientific and previously held the position of CEO at MS&C Nordics.

Emma Aneheim is the Co-Founder and Chief Science Officer of Atley Solutions. She holds a PhD in Radiopharmaceutical Chemistry from the University of Gothenburg, where she has been a key member of the pioneering Targeted Alpha Therapy Group. Her research focuses on the development of radiopharmaceuticals for targeted alpha therapy, with a particular emphasis on Astatine-211.

In recognition of her groundbreaking work, Emma was awarded a fellowship from the Swedish Cancer Foundation in 2019. She is also the inventor of the Atley C100, the world’s first commercial manufacturing system for At-211 radiopharmaceuticals.

Chiara Timperanza is a Radiochemist at Atley Solutions. She holds a Master’s degree in Chemistry from the University of Pisa and is currently pursuing a PhD at the University of Gothenburg. Her doctoral research focuses on designing and evaluating new molecules for pretargeting applications, with the aim of developing strategies for treating disseminated cancers using alpha-particle emitters.

Björn Eriksson serves as the Chief Technology Officer at Atley Solutions. He earned his PhD in Analytical Chemistry from Karlstad University, where his research focused on capillary liquid chromatography and capillary electrophoresis. Following his doctoral studies, Björn worked as an Analytical Chemist at Cambrex, collaborating with process chemists and engineers to upscale API and intermediate processes. He then served as CTO at hemCheck Sweden AB, where he played a crucial role in advancing products from early prototypes to market-ready stages. In 2020, Björn joined Atley Solutions as CTO, where he coordinates hardware and software development, contributing his extensive experience in product development within life science startups.

Johan Olsson serves as the Software Product Owner at Atley Solutions. He earned his Bachelor of Science in Electronics from the Faculty of Engineering at Lund University. Johan is bringing several years of experience in designing and developing software and electronics, particularly in the field of medical technology and devices. Since joining Atley in 2023, Johan has been responsible for electronics and software development for Atley’s commercial hardware products.

Albin serves as a Production Technician at Atley Solutions, bringing extensive experience in mechanical maintenance, manufacturing, and precision measurement. He holds a Bergtekniker diploma from Luleå University of Technology and has also served in the Swedish Military.

At Atley Solutions, Albin is responsible for the manufacturing of Atley Targets and consumables for the Atley C100.

Caroline Pamp serves as the Legal Counsel at Atley Solutions, specializing in intellectual property, corporate, and contract law. She earned her LL.D. in intellectual property law from University of Gothenburg, Sweden, and has over fifteen years of experience addressing legal issues in technology-driven startups across various sectors, including biotechnology, research instruments, nanotechnology, energy, material sciences, and information technology.

Fredrik Bergman serves as the Chairman of the Board at Atley Solutions. He is an experienced business and strategy developer within the MedTech industry. In addition to his role at Atley, Fredrik holds the position of Vice President of Business Development at Trioworld.

He holds a MSc in Mechanical Engineering at Chalmers University of Technology and a BSc in Business Administration at The School of Business, Economics and Law at the University of Gothenburg.

Emma Aneheim is the Co-Founder and Chief Science Officer of Atley Solutions. She holds a PhD in Radiopharmaceutical Chemistry from the University of Gothenburg, where she has been a key member of the pioneering Targeted Alpha Therapy Group. Her research focuses on the development of radiopharmaceuticals for targeted alpha therapy, with a particular emphasis on Astatine-211.

In recognition of her groundbreaking work, Emma was awarded a fellowship from the Swedish Cancer Foundation in 2019. She is also the inventor of the Atley C100, the world’s first commercial manufacturing system for At-211 radiopharmaceuticals.

Sture Lindegren is a Co-Founder and Deputy Board Member of Atley Solutions. He holds a PhD in Nuclear Chemistry from Chalmers University of Technology and is a founding member of the Targeted Alpha Therapy Group at the University of Gothenburg.

Sture's pioneering work has significantly advanced the development of radiopharmaceuticals, with a particular focus on At-211 for cancer treatment.